Sanofi returns rights for cancer candidate MM-121 to Merrimack

Sanofi returns rights for cancer candidate MM-121 to Merrimack


USA-based Merrimack Pharmaceuticals says it has reached an agreement with French drug major Sanofi to…

LicensingMerrimack PharmaceuticalsMM-121OncologyPharmaceuticalSanofi

Merrimack Pharmaceuticals reveals positive Phase III results in pancreatic cancer


USA-based Merrimack Pharmaceuticals has announced positive results from a Phase III study of its new…

FluorouracilHealth Medical PharmaHealth Medical PharmaMedicineMerrimack PharmaceuticalsMM-398OncologyOrganofluoridesPharmaceuticalResearchUSA

Modest growth expected for pancreatic cancer therapy market


Fueled by the increasing global prevalence of pancreatic cancer (PC), coupled with the approval of at…

Markets & MarketingMerrimack PharmaceuticalsMM-398OncologyPharmaceuticalResearchTH-302Threshold Pharmaceuticals

Merrimack Pharma is systematically driven, say analysts


USA-based Merrimack Pharmaceuticals' (Nasdaq: MACK) recent R&D day (The Pharma Letter April 11) highlighted…

FinancialMerrimack PharmaceuticalsMM-121MM-298MM-398OncologyPharmaceuticalResearch

Merrimack presents encouraging preclinical research with MM-121 in ER-positive breast cancer model


USA-based Merrimack Pharmaceuticals (Nasdaq: MACK) has announced preclinical study results showing that…

Merrimack PharmaceuticalsMM-121OncologyPharmaceuticalResearchSanofi

Back to top